Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NeuroPace ( (NPCE) ) just unveiled an announcement.
On May 27, 2025, NeuroPace announced the preliminary one-year results of its NAUTILUS study, which evaluates the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint and showed significant seizure reduction in a key patient subgroup, suggesting potential benefits for a substantial portion of patients. NeuroPace plans to engage with the FDA regarding regulatory pathways and is confident in its long-term growth strategy, reaffirming its 2025 financial guidance.
The most recent analyst rating on (NPCE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.
Spark’s Take on NPCE Stock
According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.
NeuroPace’s stock score reflects a mix of promising growth potential and significant financial challenges. Strong revenue growth and technical momentum are key strengths, but the financial struggles and valuation concerns weigh heavily. The positive guidance and corporate events provide some confidence, but the need for improved financial health and operational efficiencies remains critical.
To see Spark’s full report on NPCE stock, click here.
More about NeuroPace
NeuroPace, based in Mountain View, Calif., is a medical device company focused on improving the lives of individuals with epilepsy through its innovative RNS System, a brain-responsive platform that provides personalized, real-time treatment for drug-resistant epilepsy.
Average Trading Volume: 246,687
Technical Sentiment Signal: Buy
Current Market Cap: $579.9M
For detailed information about NPCE stock, go to TipRanks’ Stock Analysis page.